Crestor (Rosuvastatin) and PPIs (Omeprazole, Pantoprazole): Drug Interaction Guide

Crestor (rosuvastatin), a synthetic HMG-CoA reductase inhibitor, works by reducing LDL cholesterol levels. Omeprazole (Prilosec) and pantoprazole (Protonix) are PPIs employed to manage GERD, promote ulcer healing, and prevent excess stomach acid. This article focuses exclusively on rosuvastatin combined with omeprazole or pantoprazole, rather than examining statins broadly or alternative acid-reducing agents like H2 blockers.

The direct answer

Rosuvastatin and PPIs are generally considered compatible with no dose adjustment required for the combination itself. This rests on pharmacologic reasoning (separate elimination pathways) rather than a dedicated randomized trial designed to test this specific pair, so "no known interaction" is a statement about the absence of a plausible mechanism and the absence of a reported signal, not proof from a purpose-built outcome study.

Why This Combination Comes Up So Often

Patients with cardiovascular risk factors frequently also have GERD, take low-dose aspirin (which raises GI bleeding risk and prompts PPI co-prescription), or were placed on a PPI years earlier for reflux and never came off it. The result is that a large share of statin users are also on a PPI at any given time, which makes this one of the more commonly asked interaction questions in primary care and cardiology.

Mechanism: Why the Interaction Risk Is Low

Rosuvastatin is unusual among statins in how little it relies on hepatic CYP450 metabolism. According to the FDA-approved prescribing information, rosuvastatin is eliminated largely as unchanged drug through biliary/fecal excretion, with only a minor contribution from CYP2C9-mediated metabolism according to the FDA-approved prescribing information. Omeprazole is metabolized mainly by CYP2C19 and, to a lesser degree, CYP3A4; pantoprazole uses the same CYP2C19 pathway but is generally regarded as a weaker CYP2C19 inhibitor than omeprazole. Because rosuvastatin's clearance does not run through CYP2C19 or CYP3A4, the two drug classes largely avoid each other's metabolic machinery. This is different from a CYP3A4-dependent statin such as simvastatin, which does have well-documented interactions with strong CYP3A4 inhibitors.

Transporters: OATP1B1 and BCRP

Rosuvastatin depends on hepatic uptake transporters (OATP1B1, OATP1B3) and the efflux transporter BCRP. The Crestor label warns that drugs which inhibit these transporters, cyclosporine and certain HIV protease inhibitors, for example, can raise rosuvastatin plasma exposure substantially, in some cases several-fold, according to the drug's prescribing information. Standard-dose omeprazole and pantoprazole are not established as clinically relevant inhibitors of OATP1B1 or BCRP at typical acid-suppression doses. This absence of transporter overlap is the main pharmacologic reason the combination is not expected to raise rosuvastatin levels.

Gastric pH and Absorption

PPIs raise gastric pH substantially, which can affect drugs that require an acidic environment to dissolve. Rosuvastatin is formulated as a calcium salt with solubility that is not strongly pH-dependent, so PPI-induced acid suppression is not expected to meaningfully reduce rosuvastatin absorption. This is a mechanistic inference from the drug's formulation properties rather than a finding from a dedicated absorption study in PPI users, and it should be read that way.

What the evidence actually shows and does not show

No randomized controlled trial has been designed specifically to measure clinical outcomes (LDL response, myopathy, liver injury) from combined rosuvastatin-PPI therapy. What exists instead is: (1) a pharmacologic argument based on non-overlapping elimination pathways, (2) general statin-PPI observational literature looking at safety signals such as myopathy risk, and (3) absence of a disproportionate signal in adverse event surveillance. Several of these observational and pharmacokinetic studies are referenced in prior versions of statin-interaction literature, but the specific figures (odds ratios, percentage AUC changes) attached to them could not be verified against a confirmed primary source for this draft and should be checked against the original paper before being cited as a precise number. Where a number cannot be verified, this page states the direction of the finding rather than an exact figure.

The strongest available anchor for the pharmacokinetic reasoning is the FDA-approved Crestor label itself, which documents rosuvastatin's elimination pathway and lists the drugs that do meaningfully raise rosuvastatin exposure, PPIs are not among them.

Omeprazole vs. Pantoprazole: Does the Specific PPI Matter Here?

Not for the rosuvastatin question specifically. Both PPIs are believed to carry the same low-risk profile with rosuvastatin because neither depends on the transporters or enzymes rosuvastatin uses for clearance. The choice between omeprazole and pantoprazole matters more for other drug pairs: omeprazole's stronger CYP2C19 inhibition is the reason it is more often discussed alongside clopidogrel, where reduced conversion to the active metabolite has been a longstanding regulatory concern prompting an FDA safety communication about that specific pairing. That concern does not transfer to rosuvastatin, which is not activated or cleared through CYP2C19.

Shared Side Effects Worth Monitoring Even Without a Direct Interaction

Rosuvastatin and PPIs do not need to interact pharmacokinetically to create overlapping clinical risk in the same patient.

Muscle symptoms. Statins carry a class-wide risk of myalgia and, rarely, rhabdomyolysis. Long-term PPI use has been associated with hypomagnesemia, and low magnesium can independently cause muscle cramping or weakness. A patient on both drugs who develops new muscle pain deserves a creatine kinase (CK) level and a serum magnesium level, since low magnesium can mimic or amplify statin-related myopathy symptoms. Regulatory safety communications have noted that long-term PPI use, particularly beyond one year, can be associated with clinically significant magnesium depletion.

Liver enzymes. Rosuvastatin can raise transaminases, more often at higher doses. PPI-associated liver injury is uncommon but has been reported in isolated cases. Baseline and periodic ALT monitoring reasonably covers both drugs.

Bone health. Long-term PPI use (generally over a year) has been linked in observational studies to a modest increase in fracture risk, which is the basis for periodic bone-health discussion in patients on extended PPI therapy, independent of statin status. Any specific relative-risk figure for this association should be verified against the primary literature before being quoted to a patient.

Dosing and Timing

No dose adjustment of rosuvastatin or either PPI is required based on this combination alone. Rosuvastatin can be taken at any time of day with or without food. PPIs are typically dosed 30 to 60 minutes before a meal for maximal acid suppression. There is no pharmacologic reason to separate rosuvastatin and a PPI by time of day, this is different from rosuvastatin taken with aluminum- or magnesium-containing antacids, where the FDA label recommends spacing doses because antacids can reduce rosuvastatin absorption through a chelation mechanism unrelated to PPIs.

The FDA label also notes that patients of Asian ancestry have roughly double the rosuvastatin exposure of other populations and are recommended to start at a lower dose (5 mg); this is a pharmacogenomic consideration unrelated to PPI use, but it becomes more relevant whenever a patient's overall statin exposure is already higher for other reasons, per the drug's prescribing information.

Should the PPI Itself Be Reassessed?

A medication reconciliation visit that raises the statin-PPI question is also a reasonable moment to ask whether the PPI is still needed. Many patients remain on a PPI indefinitely after an initial GERD episode or H. pylori treatment without a clear ongoing indication. Conditions that generally warrant continued long-term PPI therapy include Barrett's esophagus, severe erosive esophagitis, and Zollinger-Ellison syndrome; for these patients, continuing the PPI alongside rosuvastatin is standard practice with routine monitoring, not a special-precaution scenario. Deprescribing decisions should be made with the prescribing gastroenterologist or primary care clinician, not driven by the statin interaction question.

Evidence-Status Assessment: Rosuvastatin + Omeprazole/Pantoprazole

Special Populations

Older adults. Patients 65 and older are more likely to be on both drug classes and more susceptible to PPI-associated hypomagnesemia and statin-related muscle symptoms. Guideline bodies addressing potentially inappropriate medication use in older adults have flagged long-term PPI use without a clear ongoing indication as worth periodic reassessment. Rosuvastatin clearance is not directly altered by age, but renal function tends to decline with age, and a meaningful portion of rosuvastatin is renally eliminated, so periodic eGFR checks are reasonable in this group regardless of PPI status.

Chronic kidney disease. The Crestor label recommends a lower starting dose and a lower maximum dose in patients with severe renal impairment. PPI use does not change these thresholds by itself, but reduced renal clearance combined with potential PPI-related electrolyte shifts is a reasonable basis for closer magnesium and creatinine monitoring in this group.

CYP2C19 poor metabolizers. A meaningful minority of patients, more common in some East Asian populations, are genetically poor CYP2C19 metabolizers and will have higher omeprazole exposure than typical metabolizers. This does not change rosuvastatin exposure, since rosuvastatin does not depend on CYP2C19, but it can increase the PPI's own side-effect burden (including magnesium depletion risk). If a patient on rosuvastatin and omeprazole develops unexplained hypomagnesemia, switching to pantoprazole or considering CYP2C19 status is a reasonable discussion point with the prescriber, not a rosuvastatin-specific fix.

Drugs That Actually Do Interact With Rosuvastatin

To put the PPI question in context, the FDA-approved Crestor label identifies several combinations that do require dose capping or avoidance, because they meaningfully raise rosuvastatin exposure through transporter inhibition or other mechanisms: cyclosporine, gemfibrozil, certain HIV protease inhibitor combinations (lopinavir/ritonavir, atazanavir/ritonavir), regorafenib, and darolutamide, according to the drug's prescribing information. Exact fold-change figures for each of these are listed on the label and should be checked there directly rather than relied on from memory, since label updates can revise these numbers. PPIs are not on this list because they do not act through the same transporter or enzyme pathways.

When to Seek Urgent Care

New, severe, or rapidly worsening muscle pain with dark urine (a possible sign of rhabdomyolysis), yellowing of the skin or eyes, severe abdominal pain, or signs of a GI bleed (black stools, vomiting blood) in a patient on either or both of these medications warrants urgent medical evaluation rather than waiting for a routine follow-up. These symptoms are not specific to the rosuvastatin-PPI combination but are reasons to seek care promptly regardless of which drugs a patient is taking.

References

During revision, certain quantitative assertions from earlier versions (including odds ratios, AUC percentage shifts, and attributed quotes) lacked confirmation in primary sources and have accordingly been deleted, converted to general directional language, or marked above for fact-checking prior to release.